AURKA and non-small cell lung carcinoma: We knocked down HURP in four additional NSCLC lines, two SMARCA4 mutant and two SMARCA4 wild-type, which were previously tested with siRNAs against TPX2 and AURKA. SMARCA4 mutant lines had significant decrease in cell growth or survival when HURP was depleted, whereas SMARCA4 wild-type lines were less sensitive (Fig. 5c).